Hiroyuki Izutsu

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka et al. · Annals of the Rheumatic Diseases · 2019 · 130 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka et al. · Annals of the Rheumatic Diseases · 2019 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials

Yoshiya Tanaka, Hiroyuki Izutsu · Expert Opinion on Pharmacotherapy · 2020 · 35 citations · Full text

Medicine, Internal Medicine, Pharmacology +13

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka et al. · Arthritis Research & Therapy · 2020 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka et al. · Rheumatology and Therapy · 2021 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14